Unternehmen wird geladen
Keep exploring
The themes Neogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc131,6B $A+
SYKStryker Corp.117,9B $A+
EWEdwards Lifesciences Corporation61,6B $A+
GEHCGE Healthcare Technologies Inc.37,5B $A
GKOSGlaukos Corp14,5B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Food Safety: test kits, culture media, hygiene-monitoring products and related software for food and feed testing73 %
- Animal Safety: veterinary products, pest controls, diagnostic products and animal genetics services27 %
Die Umsatzanteile sind Schätzungen für three months ended 2026-08-31 und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
- BIMbioMérieux
Was es verkauft6
Molecular Detection System
A system that tests food and environmental samples for harmful bacteria by detecting their genetic material.
Reveal tests
Single-step tests used to check food and feed for contaminants, including allergens and natural toxins.
Petrifilm plates
Ready-to-use plates that help food makers and laboratories detect and count microorganisms.
3 weitere anzeigen
Neogen Analytics
Software that gathers food testing and sanitation results so customers can review patterns and track food safety work.
Ideal and Prima Tech veterinary instruments
Tools for giving animals injections, medicines and vaccines, as well as for animal identification and breeding procedures.
Provecta
A range of products used to control parasites in companion animals.
Wer es kauft4
- Food and animal-feed producers and processors buy tests and related supplies directly or through distributors.
- Food safety laboratories and government inspection agencies buy test kits, culture media and related products.
- Veterinarians, livestock producers, ranchers, animal-health retailers and distributors buy veterinary medicines, vaccines, instruments and pest-control products.
- Breed registries, researchers and livestock and companion-animal producers use animal genetics laboratory services.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Some Petrifilm products are still manufactured at 3M facilities while Neogen prepares to move production to its Lansing site.
- 2Products depend on purchased raw materials and components, and some testing methods use technology licensed from third parties.
- 3Sales in many markets rely on distributors, while products such as veterinary medicines and pest controls depend on government approvals and registrations.
Was schiefgehen könnte
- 1Moving Petrifilm manufacturing from 3M to Neogen’s Lansing site could disrupt production or create integration and operating problems.
- 2The proposed sale of the animal genetics business depends on regulatory approvals and could be delayed or not completed.
- 3Tariffs, higher raw-material costs or supplier interruptions could raise production costs or limit product availability.
Über Neogen Corp.
Neogen sells tests and supplies that help food and animal-feed producers find bacteria, toxins, allergens and other safety or quality problems. It also sells veterinary medicines, vaccines, instruments and pest-control products to animal-health buyers. Neogen provides animal genetics laboratory services and has agreed to sell that business to Zoetis; the sale is awaiting regulatory approvals.
- Hauptsitz
- Lansing, Michigan
- Gegründet
- 1981
- Beschäftigte
- 2,636 (May 31, 2026, high)
- Notiert an
- NASDAQ
- Geschäftsjahresende
- May 31
Gebaut aus den eigenen Einreichungen von Neogen Corp. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
